Figure 3. In vivo AZD1480 treatment induces profound changes in the immune cell compostion in both the spleen and the tumor microenvironment.

MO4 tumor-bearing mice were treated with AZD1480 at 30 mg/kg or vehicle control by oral gavage twice a day for 7 days. Two hours after the last dosing mice were sacrificed and single cell suspensions of spleen and tumor were made. Different immune cell populations were subsequently analysed by flow cytometry. A. Percentage of CD45⁺CD3⁺ T cells in the spleen of treated mice. Within the CD45⁺CD3⁺ T cells the percentage of CD4⁺ and CD8⁺ T cells was determined. B. Percentage of myeloid cells (defined as CD45⁺CD11b⁺ cells) in the spleen of treated mice. Within this population the percentage of the different subsets of myeloid-derived suppressor cells (moMDSC: CD45⁺CD11b⁺Ly6C⁺Ly6G⁻ and grMDSC: CD45⁺CD11b⁺Ly6G⁺Ly6C^int) was determined. C. Percentage of CD45⁺CD3⁺ T cells in the tumor of treated mice. Within the CD45⁺CD3⁺ T cells the percentage of CD4⁺ and CD8⁺ T cells was determined. D. Percentage of myeloid cells (defined as CD45⁺CD11b⁺ cells) in the tumor of treated mice. Within this population the percentage of the different subsets of myeloid-derived suppressor cells (moMDSC: CD45⁺CD11b⁺Ly6C⁺Ly6G⁻ and grMDSC: CD45⁺CD11b⁺Ly6G⁺Ly6C^int) was determined. Three independent experiments were performed (with each time 3 mice per group) and results are presented as mean ± SEM.